MSD Korea targets antidiabetic market
Published: 2007-10-11 06:59:00
Updated: 2007-10-11 06:59:00
Industry watchers expect the domestic antidiabetic market is about to heat up, as MSD Korea's sitagliptin phosphate (Januvia), an oral diabetes medication in a new class of drugs known as DPP-4 inhibitors, will soon join the market.
Handok Pharm and GlaxoSmithKline are engaged in cutthroat co...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
